跳至主要内容
临床试验/NCT03740698
NCT03740698终止不适用

The Bio-Inspired Artificial Pancreas for the Home

Imperial College London1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2021年2月1日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
8
试验地点
1
主要终点
% Time in Target Range Defined as 3.9-10mmol/l

研究概览

简要总结

The purpose of the study is to evaluate the safety and effectiveness of a closed-loop insulin delivery system (also known as an artificial pancreas) which is made up of three components that communicate with each other:

  1. A glucose sensor that measures glucose every 5 minutes
  2. A control algorithm that calculates the required insulin dose
  3. An insulin pump that delivers the insulin calculated

详细描述

In addition to assessing the closed-loop insulin delivery system on its own, the study aims to evaluate the system when combined with a personalised bolus calculator that adapts over time. Standard bolus calculators are widely used in type 1 diabetes self-management to calculate insulin boluses at mealtimes and are incorporated in all insulin pumps and in some glucose meters. A standard bolus calculator uses a generic formula taking into account the target glucose level, current glucose level, carbohydrate content of meal (grams), insulin: carbohydrate ratio (the amount of carbohydrate (grams) covered by 1 unit of insulin), insulin sensitivity factor (the reduction in blood glucose by 1 unit of insulin) and insulin-on-board (IOB, the remaining active insulin from the previous bolus). Some bolus calculators additionally consider parameters such as exercise, but all lack the ability to automatically adapt over time to respond to individual needs.

Finally, the study aims to compare the closed-loop insulin delivery system to standard pump therapy (also known as an open-loop insulin delivery system) in combination with continuous glucose monitoring (referred to as sensor augmented pump).

The Diabetes Technology group at Imperial College have developed a unique closed-loop insulin delivery system known as the Bio-inspired Artificial Pancreas (BiAP) and a personalised bolus calculator known as the Advanced Bolus Calculator for Diabetes (ABC4D).

Overview of the complete closed-loop system (artificial pancreas) used in this study is as follows:

  1. A commercially available continuous subcutaneous glucose sensor (Dexcom G5 CGM system).
  2. The BiAP control algorithm implemented in a low-power handheld device (developed at Imperial College)
  3. An insulin infusion pump (Tandem t:slim) for insulin delivery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults over 18 years of age
  • Type 1 diabetes confirmed on the basis of clinical features and a random c-peptide <200 pmol/L
  • Type 1 diabetes for greater than 1 year
  • Continuous subcutaneous insulin infusion for greater than 6 months
  • Structured education done (either 1:1 or group education)
  • HbA1c <10% (86mmol/mol)
  • A negative pregnancy test in female participants of childbearing age

排除标准

  • More than one episode of severe hypoglycaemia (defined as hypoglycaemia requiring 3rd party assistance) in the preceding year
  • Impaired awareness of hypoglycaemia (Gold score >4)
  • Pregnant or planning pregnancy
  • Breastfeeding
  • Enrolled in other clinical trials
  • Have active malignancy or under investigation for malignancy
  • Severe visual impairment
  • Reduced manual dexterity
  • Ischaemic heart disease
  • Anti-anginal medications
  • Regular use of paracetamol
  • Unable to participate due to other factors, as assessed by the Chief Investigator

结局指标

主要结局

% Time in Target Range Defined as 3.9-10mmol/l

时间窗: 6 months

Interstitial blood glucose will be measured every 5 minutes via CGM for a period of six months (original plan) The study was terminated early. Only two participants entered the allocated study arm and remained in the study for two weeks.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

The Bio-Inspired Artificial Pancreas for the Home | 临床试验